Trial Profile
Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA But Without Clinically Detectable Residual Diseases and/or Metastases After Curative Chemoradiation - A Single Arm Phase II Trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- 05 Apr 2022 Status changed from active, no longer recruiting to terminated
- 25 Mar 2021 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 25 Mar 2021 Status changed to active, no longer recruiting.